Seltorexant

Seltorexant
Clinical data
Other namesMIN-202; JNJ-42847922; JNJ-922
Routes of
administration		By mouth[1]
Drug classOrexin antagonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismCYP3A4[2]
Elimination half-life2–3 hours[2]
Identifiers
  • [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)
  • c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3
  • InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+
  • Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N

Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia.[3][2] It is a selective antagonist of the orexin OX2 receptor (2-SORA).[2][4][1] The medication is taken by mouth.[1]

  1. ^ a b c Sun Y, Tisdale RK, Kilduff TS (2021). "Hypocretin/Orexin Receptor Pharmacology and Sleep Phases". Front Neurol Neurosci. Frontiers of Neurology and Neuroscience. 45: 22–37. doi:10.1159/000514963. ISBN 978-3-318-06843-6. PMC 8171809. PMID 34052813.
  2. ^ a b c d Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
  3. ^ "Seltorexant - Janssen Research & Development/Minerva Neurosciences". AdisInsight. 2022-02-28. Retrieved 2022-04-05.
  4. ^ Jacobson LH, Hoyer D, de Lecea L (January 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499. S2CID 248119793.